<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759198</url>
  </required_header>
  <id_info>
    <org_study_id>YH23537-202</org_study_id>
    <nct_id>NCT02759198</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo- and Active-Controlled, Multicenter, Phase 2 Trial to Evaluate the Efficacy and Safety of YH23537 in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of YH23537 versus celebrex in
      patients with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Actual">September 26, 2017</completion_date>
  <primary_completion_date type="Actual">May 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in VAS score to assess pain at Week 12</measure>
    <time_frame>baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VAS score to assess pain at Week 4, 8</measure>
    <time_frame>baseline, week 4 and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) score at Week 4, 8, 12</measure>
    <time_frame>baseline, week 4, week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC subgroup(pain, stiffness, difficulty performing daily activities) score at Week 4, 8, 12</measure>
    <time_frame>baseline, week 4, week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage From Baseline in WOMAC responder at Week 4, 8, 12</measure>
    <time_frame>baseline, week 4, week 8 and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of positive response(+1) in Patient Global Impression of Change (PGIC) at Week 12</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of positive response(excellent, good and fair response) in Physician's Global Assessment of Response to Therapy (PGART) at Week 12</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life measured by SF-12 at Week 12</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients who had taken rescue medication at week 12</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Amount of rescue medication tablets taken following the investigational product</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of days taken rescue medication following the investigational product</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Kellgren-Lawrence(KL) grading scale to assess the severity of knee osteoarthritis on a plain radiograph at Week 12</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in International knee documentation committee(IKDC) score at Week 4, 8, 12</measure>
    <time_frame>week 4, 8, 12</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">456</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>YH23537</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YH23537 750/1500/3000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>YH23537 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH23537</intervention_name>
    <description>Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg</description>
    <arm_group_label>YH23537</arm_group_label>
    <other_name>YH23537 750mg/1500mg/3000mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Drug: Celecoxib 200mg</description>
    <arm_group_label>Celebrex</arm_group_label>
    <other_name>Celecoxib 200mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH23537 placebo</intervention_name>
    <description>Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Men and women â‰¥ 40 years of age

          -  Patients with knee osteoarthritis at one or both knee by ACR

        Exclusion Criteria:

          -  Patients with known or suspected secondary knee osteoarthritis

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon Je Cho, M.D, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

